<DOC>
	<DOC>NCT00213655</DOC>
	<brief_summary>Evaluation of maintenance BCG immunotherapy (dose 27 mg) in superficial bladder tumors. Two randomized arms (every 3 or 6 months) will be studied for a population of 300 patients.</brief_summary>
	<brief_title>URO-BCG-4 : Bladder Tumors Immunotherapy</brief_title>
	<detailed_description>BCG maintenance immunotherapy 1/3 dose : 27 mg two randomized arms : 3 or 6 months for 36 months clinical side effects according to OMS score efficacy regarding recurrence : cytology and cystoscopy PSA, leucocyturia and N-ramp gene evaluation</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Ta and T1 bladder tumors BCG contraindications</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>